XML 47 R31.htm IDEA: XBRL DOCUMENT

Acquisitions and Dispositions (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:


(In millions)	PPD		PeproTech		European Viral Vector Business		Mesa Biotech		Lengnau biologics manufacturing facility		Other
Purchase price
Cash paid	$	17,237	$	1,947	$	848	$	421	$	17	$	298
Fair value of equity awards exchanged	43		—		—		—		—		—
Fair value of contingent consideration	—		—		—		65		1		117

Cash acquired	(1,244)		(83)		(18)		(14)		—		(13)
	$	16,036	$	1,864	$	830	$	472	$	18	$	402

Net assets acquired
Current assets	$	2,510	$	63	$	39	$	54	$	—	$	12
Property, plant and equipment	562		18		59		2		92		2
Definite-lived intangible assets:
Customer relationships	6,264		514		302		—		—		2
Product technology	—		282		25		279		—		224
Tradenames	603		—		—		2		—		2
Backlog	1,060		—		—		—		—		—


Goodwill	13,781		1,190		600		237		18		198
Other assets	1,108		11		3		3		376		2
Contract liabilities	(1,570)		—		(59)		—		—		(1)
Deferred tax assets (liabilities)	(1,803)		(193)		(80)		(72)		—		(28)
Finance lease liabilities	(86)		—		(24)		—		(82)		—
Debt assumed	(4,299)		—		—		—		—		—
Other liabilities assumed	(1,972)		(21)		(35)		(33)		(386)		(11)
Redeemable noncontrolling interest	(122)		—		—		—		—		—
	$	16,036	$	1,864	$	830	$	472	$	18	$	402

The components of the purchase price and net assets acquired for 2019 acquisitions are as follows:


(In millions)	Brammer Bio		Other
Purchase price
Cash paid	$	1,710	$	169



Cash acquired	(36)		—
	$	1,674	$	169

Net assets acquired
Current assets	$	52	$	58
Property, plant and equipment	147		102
Definite-lived intangible assets:
Customer relationships	744		—
Product technology	65		7
Tradenames	7		—


Goodwill	938		9
Other assets	49		—
Contract liabilities	(110)		—
Deferred tax liabilities	(110)		(6)
Other liabilities assumed	(108)		(1)
	$	1,674	$	169

Business Acquisition, Pro Forma Information [Table Text Block]

The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:


	Year Ended
	December 31,		December 31,
(In millions)	2021		2020
Revenues	$	44,886	$	36,887

Net income attributable to Thermo Fisher Scientific Inc.	$	7,369	$	5,361